Leo Pharma leaves the door open for acquisitions

The Danish pharmaceutical firm’s current pipeline is well-prepared for the future, but CEO Cristophe Bourdon still won’t rule out new additions, should an acquisition opportunity arise.

Christophe Bourdon, CEO of Leo Pharma | Photo: Orphazyme / PR

Christophe Bourdon, who assumed charge of Leo Pharma in April, is satisfied with the current state of the pharmaceutical firm’s pipeline, which he tells Danish business media Børsen is strongly positioned for an upcoming initial public offering.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs